PHARMACY

NY legislators green light delay of e-prescribing mandate

BY Antoinette Alexander

NEW YORK — State legislators have passed legislation delaying implementation of an e-prescribing mandate given a lack of readiness among both physicians and electronic health records vendors, according to published reports.

The implementation of the legislation, originally slated for March 27, has been delayed until March 2016, according to reports. The legislation still requires a signature by Gov. Andrew Cuomo.

The legislation, which would apply to both controlled and non-controlled substances, is designed to curb fraud and prescription errors.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Cardinal taps Calla for industry relations role

BY Ryan Chavis

DUBLIN, Ohio — Cardinal Health announced the appointment of Nick Calla to the role of VP industry relations, Cardinal Health Specialty Solutions. According to the company, Calla will focus on the creation of specialty pharmacy programs that connect manufacturers with its retail independent pharmacies — including the development of the Specialty Pharmacy Alliance, a specialty resource center.
 
Before joining Cardinal Health, Calla served as VP trade relations for the Community Specialty Pharmacy Network, where he was in charge of business development and relationship management with manufacturers around the country. He also worked for Walgreens Specialty Pharmacy for seven years, as well as director of clinical programs and network administration for Eckerd Health Services.
 
Additionally, Nick also was president and general manager of Oncology Pathways, a group purchase organization founded by the UPMC Cancer Center and Medmark Specialty Pharmacy. His experience working with the pharmaceutical manufacturing and retail pharmacy communities will be a great asset to the team.
 
Calla earned his bachelors of pharmacy degree from the University of Pittsburgh and a juris doctorate from Duquesne University. He has completed fellowship programs at the University of Pennsylvania, University of Southern California and Harvard University. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Mylan closes deal on Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business

BY Michael Johnsen

POTTERS BAR, England — Mylan on Friday announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.
 
"Today marks the beginning of the next exciting chapter of growth for Mylan," stated Robert Coury, Mylan executive chairman. "With the completion of this transaction, we will benefit from significantly enhanced financial flexibility, an optimized global tax structure and greater balance sheet capacity, all of which position us exceptionally well for future opportunities."
 
Under the previously announced terms of the transaction agreement, Abbott received 110 million shares of Mylan, resulting in former Mylan shareholders now owning approximately 78% of Mylan and Abbott now owning approximately 22% of Mylan. 
 
Mylan and Abbott's non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan executive team. The company will trade on Nasdaq under the ticker symbol MYL.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?